Genetically Modified Mesenchymal Stem
|dc.identifier.citation||Griffin, M., Greiser, U., Barry, F., O'Brien, T., & Ritter, T. (2010). Genetically modified mesenchymal stem cells and their clinical potential in acute cardiovascular disease. Discovery Medicine, 9(46), 219-223.||en|
|dc.description.abstract||Adult mesenchymal stem cells (MSCs) are non-hematopoietic cells with multi-lineage potential to differentiate into various tissues of mesodermal origin. They can be isolated from bone marrow and other tissues and have the capacity to extensively proliferate in vitro. Moreover, MSCs have also been shown to produce anti-inflammatory molecules which can modulate humoral and cellular immune responses. Considering their regenerative potential and immunoregulatory effect, MSC therapy is a promising tool in the treatment of degenerative, inflammatory, and autoimmune diseases. However, the current understanding from results of clinical trials is that MSC-therapy is safe but its therapeutic efficiency needs to be improved. In this article we will focus on options for genetic manipulation of MSCs and on current progress in adapting genetically-modified MSCs for clinical use in acute cardiovascular disease.||en|
|dc.description.sponsorship||Health Research Board||en|
|dc.title||Genetically Modified Mesenchymal Stem||en|
Files in this item
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. Please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.
The following license files are associated with this item: